The neurovascular unit (NVU) represents a sophisticated multicellular system comprising endothelial cells, pericytes, astrocytes, neurons, and extracellular matrix components that collectively regulate cerebral blood flow (CBF), maintain blood-brain barrier (BBB) integrity, and support neural function. Signaling within this unit is essential for coupling neuronal activity to blood flow (neurovascular coupling), delivering nutrients, removing waste, and protecting the brain from harmful substances. Dysfunction in neurovascular signaling has emerged as a critical contributor to neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). This pathway page examines the signaling mechanisms within the NVU and their implications for neurodegeneration. [1]
The neurovascular unit consists of tightly integrated cellular components: [2]
| Component | Key Functions | Key Signaling Molecules | [3]
|-----------|---------------|----------------------| [4]
| Cerebral endothelial cells | Blood-brain barrier, transport, vasodilation | NO, prostaglandins, endothelin-1 | [5]
| Pericytes | Capillary regulation, BBB maintenance | PDGF-BB, Ang-1, TGF-β | [6]
| Astrocyte endfeet | K+ buffering, vasomodulation | ATP, glutamate, D-serine | [7]
| Neurons | Neurovascular coupling, metabolic demand signaling | Nitric oxide, prostaglandins | [8]
| Smooth muscle cells | Arteriolar tone regulation | Endothelin-1, NO | [9]
Neuronal nitric oxide synthase (nNOS) produces nitric oxide (NO) in response to neuronal activity. NO diffuses to nearby blood vessels causing vasodilation through activation of soluble guanylyl cyclase (sGC) and subsequent smooth muscle relaxation. This represents a primary mechanism of neurovascular coupling—the process by which increased neuronal activity triggers increased local cerebral blood flow. [10]
In AD, endothelial NO signaling is impaired due to: [11]
The resulting dysfunction contributes to hypoperfusion and impaired clearance of metabolic waste. [12]
Endothelin-1 (ET-1) is a potent vasoconstrictor produced by endothelial cells and astrocytes. ET-1 acts on ETA and ETB receptors on smooth muscle cells and pericytes to regulate vascular tone. In neurodegeneration, ET-1 expression is upregulated, contributing to: [13]
ET-1 receptor antagonists are being explored as therapeutic agents for vascular cognitive impairment.
Pericytes express PDGF receptor-β (PDGFR-β) and are recruited to developing vasculature by PDGF-BB secreted from endothelial cells. This signaling is critical for:
In adult brain, PDGF-BB continues to regulate pericyte function. Pericyte loss in AD correlates with BBB breakdown and cognitive decline.
TGF-β signaling from endothelial cells to pericytes regulates:
TGF-β signaling impairment contributes to pericyte dysfunction and vascular rarefaction in neurodegeneration.
Astrocytes extend endfeet that ensheath cerebral blood vessels. Calcium elevations in endfeet trigger release of vasomodulatory substances:
This astrocyte-mediated signaling contributes significantly to neurovascular coupling.
Astrocyte endfeet highly express inward-rectifier potassium (Kir) and volume-regulated anion channels (VRACs). These channels:
Kir4.1 channel dysfunction in astrocytes impairs K+ buffering and contributes to neuronal hyperexcitability.
The BBB is maintained by tight junctions between endothelial cells comprising claudins, occludin, and junctional adhesion molecules (JAMs). Signaling pathways regulating tight junction integrity include:
In AD and PD, tight junction proteins are downregulated, contributing to BBB leakage.
Transporters at the BBB include:
Aβ interacts with RAGE (Receptor for Advanced Glycation Endproducts) at the BBB, facilitating its entry into brain and promoting neuroinflammation.
VEGF-A is the primary angiogenic factor, acting through VEGFR-2 on endothelial cells. Beyond angiogenesis, VEGF has direct neural effects:
In AD, VEGF dysregulation contributes to:
Endothelial cells produce "angiocrine" factors that have paracrine effects on neural cells:
Dysfunction of angiocrine signaling contributes to neurodegeneration.
NOTCH3 is predominantly expressed in vascular smooth muscle cells and pericytes. Mutations in NOTCH3 cause CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), a hereditary small vessel disease.
NOTCH3 signaling regulates:
In sporadic small vessel disease and AD, NOTCH3 signaling is impaired, contributing to vascular dysfunction.
Aβ deposition in cerebral vessels characterizes CAA, which:
The perivascular drainage pathway, which clears Aβ along basement membranes, is compromised in CAA.
Chronic cerebral hypoperfusion:
Vascular risk factors (hypertension, diabetes, hypercholesterolemia) are established AD risk factors.
A comprehensive model of AD includes NVU dysfunction:
PD involves cerebrovascular abnormalities beyond dopaminergic neuron loss:
Vascular parkinsonism results from cerebrovascular disease affecting:
Differentiating idiopathic PD from vascular parkinsonism is clinically important.
Pericyte loss and dysfunction in PD:
| Approach | Target | Status | Potential |
|---|---|---|---|
| Recombinant tPA | Thrombolysis | Approved | Acute stroke in PD |
| Cerebrolysin | Neurotrophic | Approved | Vascular cognitive impairment |
| Statins | Cholesterol | Approved | Stroke prevention |
| Antihypertensives | Blood pressure | Approved | Vascular risk reduction |
| VEGF modulators | Angiogenesis | Experimental | Neuroprotection |
| Pericyte transplant | BBB repair | Experimental | NVU restoration |
This pathway page was created as part of the NeuroWiki mechanistic model expansion. Last updated: 2026-03-10.
'Iadecola C. The neurovascular unit coming of age: A journey through neurovascular coupling in health and disease. J Neurosci. 2017'. 2017. ↩︎
Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci. 2011. 2011. ↩︎
Sweeney MD, et al. 'Blood-brain barrier: From physiology to disease and back. Physiol Rev. 2019'. 2019. ↩︎
Bell RD, et al. 'Pericytes: Critical targets in microvascular dysfunction and neurovascular unit remodeling in Alzheimer''s disease. Acta Neuropathol. 2012'. 2012. ↩︎
Takano T, et al. Astrocyte-mediated control of cerebral blood flow. Nat Neurosci. 2006. 2006. ↩︎
Wardlaw JM, et al. 'Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and dementia: Evidence from neuroimaging and pathology. Brain. 2023'. 2023. ↩︎
Nelson AR, et al. Neurovascular dysfunction and neurodegeneration in Alzheimer's disease. Clin Sci (Lond). 2017. 2017. ↩︎
Joutel A, et al. Cerebrovascular dysfunction and microvasculopathy in CADASIL. Ann Neurol. 2010. 2010. ↩︎
Zhang WW, et al. VEGF and its receptors in Alzheimer's disease. J Alzheimers Dis. 2021. 2021. ↩︎
Yang AC, et al. Physiological and pathological functions of the neurovascular unit. Front Cell Neurosci. 2022. 2022. ↩︎
Kisler K, et al. Pericyte dysfunction in Alzheimer's disease. Cell Mol Neurobiol. 2020. 2020. ↩︎
Yamazaki Y, et al. Role of neurovascular unit in the pathogenesis of Alzheimer's disease. J Neurochem. 2021. 2021. ↩︎
Chaudhuri JD. The blood brain barrier and its significance in neurodegenerative diseases. Neurochem Res. 2022. 2022. ↩︎